What Researchers Did
Researchers compared the costs and health outcomes of adding hyperbaric oxygen therapy (HBOT) to standard care against standard care alone for diabetic foot ulcers with poor blood supply, using data from a randomised trial.
What They Found
In this economic analysis of the DAMO2CLES randomised trial, adding HBOT to standard care showed no significant difference in costs, limb salvage or health status compared with standard care alone over 12 months. The trial included 120 patients, with 60 given HBOT plus standard care and 60 given standard care. The cost difference was not significant, and the cost per limb saved was an ICER of 37,912 euros, with a very wide confidence interval from minus 112,188 to 1,063,561 euros. Average quality-adjusted life years were 0.54 with HBOT plus standard care and 0.56 with standard care alone, a difference that was not significant. For Wagner stage III/IV ulcers, the authors reported a trend toward better effectiveness and cost-effectiveness, while HBOT showed no benefit for Wagner stage II.
What This Means for Canadian Patients
For people with ischaemic diabetic foot ulcers, this study found no significant gains in limb salvage or health status from adding HBOT to standard care, and no significant cost difference. The Wagner stage III/IV trend was described as a trend only, and the abstract did not report it as a confirmed benefit. Patients can discuss these findings with their care team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The confidence intervals for the cost and cost-effectiveness results were very wide and included zero or negative values, and the Wagner stage subgroup findings were only a trend, so the study could not show clear differences.